OVERVIEW

2021 Hemostasis and Thrombosis Research Society (HTRS) Scientific Symposium is organized by Hemostasis and Thrombosis Research Society (HTRS) and will be held from Mar 10 - 12, 2021.

Accreditation:
Physician Continuing Medical Education:
The Postgraduate Institute for Medicine designates this live activity for a maximum of 10.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education:
The maximum number of hours awarded for this Continuing Nursing Education activity is 10.5 contact hours. Pharmacotherapy contact hours for Advance Practice Registered Nurses to be determined.

Continuing Pharmacy Education:
Postgraduate Institute for Medicine designates this continuing education activity for 10.5 contact hour(s) (0.105CEUs) of the Accreditation Council for Pharmacy Education.

Interprofessional Continuing Education:
This activity was planned by and for the healthcare team, and learners will receive 12.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

Description:
That meeting now seems like a distant memory. COVID-19 has forever changed our world, but what hasn’t changed is our determination to provide HTRS members and all healthcare professionals interested in hemostasis and thrombosis with access to diverse and engaging programs for continuing medical education, mentoring, research funding, and career development.

HTRS offers a full week of virtual programming for all career levels including the Trainee Workshop (Residents or Fellows), Research Colloquium (Junior Faculty and Early-Stage Investigators, plus other interested attendees), and the Multidisciplinary Pre-Conference.

Educational Objectives:
After completing this activity, the participant should be better able to:

Learning Objective for Pre-conference Session 1: “New Therapies”
At the close of this session, attendees will be able to:
• Discuss new treatment options available to patients with bleeding and clotting disorders
• Describe how new inhibitor treatments can affect laboratory test results
• Analyze how treatment of bleeding and clotting disorders can be tailored using specific therapies

Learning Objective for Pre-conference Session 2: “Inclusive Care”
At the close of this session, attendees will be able to:
• Explain the approach for gender-affirming medication treatment for gender dysphoria/incongruence
• Describe the potential adverse reactions of estrogen/testosterone treatment and develop strategies to minimize risk
• Explain the relationship between trauma, behavior, and health outcomes
• Develop strategies that promote the implementation of trauma informed care in their practice

Learning Objectives for Scientific Session 1: “The Future of Hemophilia Therapeutics: Substitution or Gene Therapy?” Debate
At the close of this session, attendees will be able to:
• Explain the current state of development of gene therapy for hemophilia
• Compare and contrast the advantages and disadvantages of protein replacement therapy and gene therapy
• Describe the safety profiles of protein replacement therapy and gene therapy

Learning Objective for Scientific Session 2: State-of-the-Art Lecture and COVID-19
• At the close of this session, attendees will be able to describe the current state of clinical, translational, and basic scientific studies investigating thrombotic and bleeding complications associated with SARS-CoV-2 infection.

Learning Objectives for Scientific Session 3-A: “Bench, Clinic, and Everything In-Between: Platelet Transfusion”
At the close of this session, attendees will be able to:
• Describe platelet transfusion practices in the REDS-III pediatric cohort
• Discuss whether the pathogen reduction process might impact antibody mediated platelet refractoriness
• Analyze data from murine model to determine whether platelets can serve as adjuvants to recipient RBC alloantibody responses

Learning Objective for Scientific Session 3-B: “Bench, Clinic, and Everything In-Between: Sickle Cell-Associated Thrombosis”
• At the close of this session, attendees will be able to describe ongoing clinical, translational, and biochemical studies investigating sickle-cell associate thrombosis.

Learning Objectives for Scientific Session 3-C: “Bench, Clinic, and Everything In-Between: Post-Thrombotic Syndrome”
At the close of this session, attendees will be able to:
• Explain the importance of the post-thrombotic syndrome (PTS) as a complication of deep venous thrombosis
• Summarize risk factors and prevention and management strategies for PTS
• Define and discuss the concept of post-pulmonary embolism syndrome